Iodine-123-vasoactive intestinal peptide receptor scanning in patients with pancreatic cancer.

Raderer M, Kurtaran A, Yang Q, Meghdadi S, Vorbeck F, Hejna M, Angelberger P, Kornek G, Pidlich J, Scheithauer W, Virgolini I

Journal of nuclear medicine : official publication, Society of Nuclear Medicine1 Sept 1998Cited by 21 (Europe PMC)

PMID9744345PepBankPUB-09744345

Publisher pageAsk about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 6 results from people.

01HumanObservational studyOther
The overall sensitivity of the 123I-VIP scan for primary pancreatic adenocarcinoma was 58% (27 of 46 scans).
In plain wordsThe VIP scan found the main pancreatic tumor in 58% of scans.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableOverall 123I-VIP scan sensitivity for primary pancreatic adenocarcinoma
Study
n = 46
Outcome group
Tumor growth · Cancer
Studied dose
150-200 MBq (approximately 1 microg VIP)As given in this study (human).
Measurements
Sensitivity
58%
primary pancreatic adenocarcinoma, 27/46 scans
Source sentences
Summary
The overall 123I-VIP scan sensitivity for primary pancreatic adenocarcinomas was 58% (27/46 scans).
2 context sentences(design, population, supporting numbers)
Summary · context
Sixty consecutive patients (26 women, 34 men; mean age 59 yr) with histologically verified pancreatic cancer were investigated in this study.
Summary · context
Iodine-123-VIP (150-200 MBq; approximately 1 microg VIP) was administered to all patients.
Report a problemFND-0974434503
02HumanObservational studyOther
123I-VIP scanning imaged liver metastases in 29 of 32 patients (sensitivity 90%).
In plain wordsIn people with pancreatic cancer, the VIP scan showed liver spread in 29 of 32 patients.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicable123I-VIP scan sensitivity for liver metastases
Study
n = 32
Outcome group
Tumor growth · Cancer
Studied dose
150-200 MBq (approximately 1 microg VIP)As given in this study (human).
Measurements
Sensitivity
90%
liver metastases, 29/32 patients
Source sentences
Summary
Liver metastases were imaged in 29/32 patients (scan sensitivity 90%)
2 context sentences(design, population, supporting numbers)
Summary · context
Sixty consecutive patients (26 women, 34 men; mean age 59 yr) with histologically verified pancreatic cancer were investigated in this study.
Summary · context
Iodine-123-VIP (150-200 MBq; approximately 1 microg VIP) was administered to all patients.
Report a problemFND-0974434504
03HumanObservational studyOther
In patients with locoregional disease and liver metastases, 123I-VIP scanning visualized the primary pancreatic tumor in 8 of 25 patients (32%).
In plain wordsIn people with pancreatic cancer that had spread, the VIP scan showed the main tumor in 8 of 25 patients.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableVisualization of primary tumors with liver metastases by 123I-VIP
Study
n = 25
Outcome group
Tumor growth · Cancer
Studied dose
150-200 MBq (approximately 1 microg VIP)As given in this study (human).
Measurements
Visualization rate
32%
locoregional and liver metastatic disease
Source sentences
Summary
and in 8/25 patients (32%) suffering both from locoregional and disease metastatic to the liver.
2 context sentences(design, population, supporting numbers)
Summary · context
Sixty consecutive patients (26 women, 34 men; mean age 59 yr) with histologically verified pancreatic cancer were investigated in this study.
Summary · context
Iodine-123-VIP (150-200 MBq; approximately 1 microg VIP) was administered to all patients.
Report a problemFND-0974434502
04HumanObservational studyOther
In patients with pancreatic cancer confined to the pancreas, 123I-VIP scanning visualized the primary tumor in 19 of 21 patients (90%).
In plain wordsIn people with pancreatic cancer limited to the pancreas, the VIP scan showed the tumor in 19 of 21 patients.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableVisualization of organ-confined primary pancreatic tumors by 123I-VIP
Study
n = 21
Outcome group
Tumor growth · Cancer
Studied dose
150-200 MBq (approximately 1 microg VIP)As given in this study (human).
Measurements
Visualization rate
90%
disease confined to the pancreas
Source sentences
Summary
Primary pancreatic tumors were visualized by 123I-VIP in 19/21 patients (90%) with disease confined to the pancreas
2 context sentences(design, population, supporting numbers)
Summary · context
Sixty consecutive patients (26 women, 34 men; mean age 59 yr) with histologically verified pancreatic cancer were investigated in this study.
Summary · context
Iodine-123-VIP (150-200 MBq; approximately 1 microg VIP) was administered to all patients.
Report a problemFND-0974434501
05HumanObservational studyOther
123I-VIP scanning imaged abdominal lymph node metastases in 4 of 5 patients.
In plain wordsIn people with pancreatic cancer, the VIP scan showed lymph node spread in 4 of 5 patients.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicable123I-VIP imaging of abdominal lymph node metastases
Study
n = 5
Outcome group
Tumor growth · Cancer
Studied dose
150-200 MBq (approximately 1 microg VIP)As given in this study (human).
Source sentences
Summary
and abdominal lymph node metastases in 4/5 patients.
2 context sentences(design, population, supporting numbers)
Summary · context
Sixty consecutive patients (26 women, 34 men; mean age 59 yr) with histologically verified pancreatic cancer were investigated in this study.
Summary · context
Iodine-123-VIP (150-200 MBq; approximately 1 microg VIP) was administered to all patients.
Report a problemFND-0974434505
06HumanObservational studyOther
In 5 patients with pancreatic cancer, the 123I-VIP receptor scan indicated the malignant lesion before CT did.
In plain wordsIn 5 people with pancreatic cancer, the VIP scan showed the tumor before a CT scan did.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableVIP scan indication of malignant lesion before CT
Study
n: not reported in source
Outcome group
Tumor growth · Cancer
Studied dose
150-200 MBq (approximately 1 microg VIP)As given in this study (human).
Measurements
Patients
5 patients
scan positive before CT
Source sentences
Summary
In 5 patients, the VIP receptor scan indicated the malignant lesion before CT.
2 context sentences(design, population, supporting numbers)
Summary · context
Sixty consecutive patients (26 women, 34 men; mean age 59 yr) with histologically verified pancreatic cancer were investigated in this study.
Summary · context
Iodine-123-VIP (150-200 MBq; approximately 1 microg VIP) was administered to all patients.
Report a problemFND-0974434506
07LabIn vitro (cells)Activity measurement
In primary pancreatic tumor cells and PANC1 adenocarcinoma cells, 123I-VIP showed specific binding in vitro.
In plain wordsIn lab tests, VIP bound specifically to pancreatic tumor cells and to PANC1 cancer cells.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableSpecific binding of 123I-VIP to pancreatic tumor cells
Study
humann: not reported in source
primary pancreatic tumor cells and PANC1 adenocarcinoma cells
Outcome group
Receptor activity and mechanism · Cancer
Studied dose
Dose not stated
Source sentences
Summary
In vitro results confirmed specific binding of 123I-VIP to primary pancreatic tumor cells as well as to PANC1 adenocarcinoma cells.
Report a problemFND-0974434507

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.